Literature DB >> 27500213

Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys.

Cheng Yang1, Sarah A Hosgood2, Patel Meeta2, Yaqiu Long3, Tongyu Zhu1, Michael L Nicholson1, Bin Yang4.   

Abstract

UNLABELLED: There is a critical need to better preserve isolated organs before transplantation. We developed a novel nonerythropoiesis cyclic helix B peptide (CHBP) derived from erythropoietin, which has potent tissue protection and prolonged serum stability. The renoprotection and potential mechanism of CHBP were evaluated in a kidney preservation model.
MATERIALS AND METHODS: Porcine kidneys (n = 5) subjected to 20-minute warm ischemia were retrieved and flushed with hyperosmolar citrate to mimic deceased donation. The kidneys and autologous blood ± 10.56 nmol/L CHBP were placed in cold storage (CS) for 18 hours. These kidneys were then normothermically hemoreperfused for 3 hours using an isolated organ perfusion system. The renal function and structure, apoptosis, inflammation, and expression of caspase-3 and heat shock protein 70 (HSP70) were assessed.
RESULTS: Cyclic helix B peptide significantly increased the renal blood flow, oxygen consumption, and urine output during reperfusion, but decreased serum potassium and renal tissue damage. Apoptotic cells were significantly decreased in the tubular areas, but increased in the lumens and interstitial areas in the post-CS and postreperfused kidneys, whereas myeloperoxidase+ cells were reduced. In addition, the expression of both caspase-3 precursor and active subunits was downregulated by CHBP in reperfused kidneys. However, HSP70 was upregulated in the post-CS and postreperfused kidneys treated with CHBP.
CONCLUSIONS: Cyclic helix B peptide administered into preservation and reperfusion solutions ameliorated renal ischemia-reperfusion injury, which might be associated with decreased apoptosis, inflammation and caspase-3, but increased HSP70. This novel preservation approach using CHBP may be applied in a porcine kidney transplant model and potential human donor kidney preservation.

Entities:  

Year:  2015        PMID: 27500213      PMCID: PMC4946457          DOI: 10.1097/TXD.0000000000000515

Source DB:  PubMed          Journal:  Transplant Direct        ISSN: 2373-8731


  41 in total

1.  Apoptotic cell death is initiated during normothermic ischemia in human kidneys.

Authors:  Tim G A M Wolfs; Bart de Vries; Sarah J Walter; Carine J Peutz-Kootstra; L W Ernest van Heurn; Gosse O N Oosterhof; Wim A Buurman
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

2.  Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-1β in isolated hemoperfused kidneys.

Authors:  Bin Yang; Sarah A Hosgood; Atul Bagul; Helen L Waller; Michael L Nicholson
Journal:  Eur J Pharmacol       Date:  2011-04-09       Impact factor: 4.432

3.  Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation.

Authors:  Linkun Hu; Cheng Yang; Tian Zhao; Ming Xu; Qunye Tang; Bin Yang; Ruiming Rong; Tongyu Zhu
Journal:  J Surg Res       Date:  2011-07-19       Impact factor: 2.192

4.  Serum-stabilized naked caspase-3 siRNA protects autotransplant kidneys in a porcine model.

Authors:  Cheng Yang; Tian Zhao; Zitong Zhao; Yichen Jia; Long Li; Yufang Zhang; Mangen Song; Ruiming Rong; Ming Xu; Michael L Nicholson; Tongyu Zhu; Bin Yang
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

5.  Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury.

Authors:  Nimesh S A Patel; Hannah L Kerr-Peterson; Michael Brines; Massimo Collino; Mara Rogazzo; Roberto Fantozzi; Elizabeth G Wood; Florence L Johnson; Muhammad M Yaqoob; Anthony Cerami; Christoph Thiemermann
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

6.  Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery.

Authors:  J C Plumier; B M Ross; R W Currie; C E Angelidis; H Kazlaris; G Kollias; G N Pagoulatos
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Helix B surface peptide administered after insult of ischemia reperfusion improved renal function, structure and apoptosis through beta common receptor/erythropoietin receptor and PI3K/Akt pathway in a murine model.

Authors:  Cheng Yang; Tian Zhao; Miao Lin; Zitong Zhao; Linkun Hu; Yichen Jia; Yinjia Xue; Ming Xu; Qunye Tang; Bin Yang; Ruiming Rong; Tongyu Zhu
Journal:  Exp Biol Med (Maywood)       Date:  2013-01

8.  Effects of erythropoietin on ischaemia/reperfusion injury in a controlled nonheart beating donor kidney model.

Authors:  Atul Bagul; Sarah A Hosgood; Monika Kaushik; Michael L Nicholson
Journal:  Transpl Int       Date:  2008-01-21       Impact factor: 3.782

9.  Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney.

Authors:  Chul Woo Yang; Can Li; Ju Young Jung; Seok Joon Shin; Bum Soon Choi; Sun Woo Lim; Bo Kyung Sun; Yong Soo Kim; Jin Kim; Yoon Sik Chang; Byung Kee Bang
Journal:  FASEB J       Date:  2003-07-18       Impact factor: 5.191

10.  Normothermic regional perfusion for donation after circulatory death without prior heparinization.

Authors:  Andrew J Butler; Lucy V Randle; Christopher Je Watson
Journal:  Transplantation       Date:  2014-06-27       Impact factor: 4.939

View more
  9 in total

1.  Sirt3 suppresses calcium oxalate-induced renal tubular epithelial cell injury via modification of FoxO3a-mediated autophagy.

Authors:  Yonghan Peng; Cheng Yang; Xiaolei Shi; Ling Li; Hao Dong; Changcheng Liu; Ziyu Fang; Zeyu Wang; Shaoxiong Ming; Min Liu; Bin Xie; Xiaofeng Gao; Yinghao Sun
Journal:  Cell Death Dis       Date:  2019-01-15       Impact factor: 8.469

2.  Erythropoietin Derived Peptide Improved Endoplasmic Reticulum Stress and Ischemia-Reperfusion Related Cellular and Renal Injury.

Authors:  Yufang Zhang; Qian Wang; Aifen Liu; Yuanyuan Wu; Feng Liu; Hui Wang; Tongyu Zhu; Yaping Fan; Bin Yang
Journal:  Front Med (Lausanne)       Date:  2020-01-24

Review 3.  Erythropoietin and its derivatives: from tissue protection to immune regulation.

Authors:  Bo Peng; Gangcheng Kong; Cheng Yang; Yingzi Ming
Journal:  Cell Death Dis       Date:  2020-02-03       Impact factor: 8.469

4.  Preservation Solutions for Kidney Transplantation: History, Advances and Mechanisms.

Authors:  Yimeng Chen; Jian Shi; Terry C Xia; Renfang Xu; Xiaozhou He; Ying Xia
Journal:  Cell Transplant       Date:  2019-08-26       Impact factor: 4.064

Review 5.  Ex-vivo Kidney Machine Perfusion: Therapeutic Potential.

Authors:  Ruta Zulpaite; Povilas Miknevicius; Bettina Leber; Kestutis Strupas; Philipp Stiegler; Peter Schemmer
Journal:  Front Med (Lausanne)       Date:  2021-12-24

6.  Properdin Deficiency Impairs Phagocytosis and Enhances Injury at Kidney Repair Phase Post Ischemia-Reperfusion.

Authors:  Yuanyuan Wu; Zinah D Zwaini; Nigel J Brunskill; Xinyue Zhang; Hui Wang; Ravinder Chana; Cordula M Stover; Bin Yang
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561

Review 7.  Large animal models for translational research in acute kidney injury.

Authors:  Balamurugan Packialakshmi; Ian J Stewart; David M Burmeister; Kevin K Chung; Xiaoming Zhou
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

8.  Long-Term Protection of CHBP Against Combinational Renal Injury Induced by Both Ischemia-Reperfusion and Cyclosporine A in Mice.

Authors:  Yufang Zhang; Yuanyuan Wu; Wei Wang; Feng Liu; Yiwen Zhang; Cheng Yang; Aifen Liu; Jing Wu; Tongyu Zhu; Michael L Nicholson; Yaping Fan; Bin Yang
Journal:  Front Immunol       Date:  2021-07-26       Impact factor: 7.561

Review 9.  Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion.

Authors:  Yuanyuan Wu; Bin Yang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.